Search - tctmd.com

Displaying 561 - 580 of 595

Sort: Relevancy | Date

News Daily News

American Heart Association Annual Stats: Yet Again, CVD Is the Leading Killer

Shelley Wood

January 26, 2017

News Features

Be It Resolved: E-Cigarettes May Help Smokers Cut Back, but Quit Altogether? The Jury’s Out

Caitlin E. Cox

January 20, 2017

News Daily News

Conflicts of Interest in the 2013 Cholesterol Guidelines? New Analysis Revisits the Controversy

Caitlin E. Cox

January 17, 2017

News Daily News

FDA’s Latest Move Against Aspirin for CVD Primary Prevention: A Picture Is Worth 11 Words

Shelley Wood

January 13, 2017

News Features

Be It Resolved: How Alcohol Harms or Helps the Heart Remains Controversial—and Confusing

Shelley Wood

January 04, 2017

News Daily News

USPSTF: Counseling on Diet and Exercise Helpful but Not Mandatory for CVD Prevention

Caitlin E. Cox

December 02, 2016

News Conference News AHA 2016

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

Racial Differences in How Patients Perceive CVD Risk Should Spur Rethink in Management

Yael L. Maxwell

November 16, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

Caitlin E. Cox

October 29, 2016

News Daily News

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Michael O'Riordan

September 16, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

News Daily News

尽管有战乱和冲突，但缺血性心脏病的死亡率仍然迎来了“阿拉伯之春”

Michael O'Riordan

August 26, 2016

News Daily News

Despite War and Strife, Ischemic Heart Disease Leads Deaths in ‘Arab Spring’

Michael O'Riordan

August 26, 2016

News Daily News

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

Michael O'Riordan

August 16, 2016

News Daily News

AHA Makes Case for Palliative Care in Advanced Cardiovascular Disease and Stroke

Todd Neale

August 11, 2016

News Daily News

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

L.A. McKeown

July 28, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

Michael O'Riordan

March 08, 2016

Advertisement

American Heart Association Annual Stats: Yet Again, CVD Is the Leading Killer

Be It Resolved: E-Cigarettes May Help Smokers Cut Back, but Quit Altogether? The Jury’s Out

Conflicts of Interest in the 2013 Cholesterol Guidelines? New Analysis Revisits the Controversy

FDA’s Latest Move Against Aspirin for CVD Primary Prevention: A Picture Is Worth 11 Words

Be It Resolved: How Alcohol Harms or Helps the Heart Remains Controversial—and Confusing

USPSTF: Counseling on Diet and Exercise Helpful but Not Mandatory for CVD Prevention

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

Racial Differences in How Patients Perceive CVD Risk Should Spur Rethink in Management

TCTMD’s Top 10 Most Popular Stories for October 2016

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

尽管有战乱和冲突，但缺血性心脏病的死亡率仍然迎来了“阿拉伯之春”

Despite War and Strife, Ischemic Heart Disease Leads Deaths in ‘Arab Spring’

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

AHA Makes Case for Palliative Care in Advanced Cardiovascular Disease and Stroke

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content